General
Preferred name
PF-06700841
Synonyms
PF-06700841, Brepocitinib ()
BREPOCITINIB ()
PF-06700841 tosylate ()
Pf-06700841 ()
PF-06700841-15 ()
BREPOCITINIB TOSYLATE ()
P&D ID
PD120281
CAS
1883299-62-4
2140301-96-6
Tags
available
drug candidate
Drug indication
Asthma
Plaque psoriasis
Psoriasis vulgaris
Drug Status
investigational
Max Phase
3.0
1.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Brepocitinib (PF-06700841) is a dual Janus kinase 1 (JAK1) and TYK2 inhibitor . It is proposed for treating autoimmune and other inflammatory conditions. Brepocitinib is a Type 1 ATP site inhibitor.
(GtoPdb)
DESCRIPTION
PF-06700841 is a potent and selective inhibitor of TYK2 and JAK1. It has the potential to treat plaque psoriasis and lupus erythematosus.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
7
BOC Sciences Bioactive Compounds
ChEMBL Drugs
DrugBank
DrugMAP
Enamine BioReference Compounds
Guide to Pharmacology
PKIDB
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
19
Molecular Weight
389.18
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
5
Aromatic Ring Count
2
cLogP
1.79
TPSA
79.18
Fraction CSP3
0.56
Chiral centers
3.0
Largest ring
6.0
QED
0.86
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Source data
